The Effect of Chemotherapeutic Agents Used in Breast Cancer Treatment on the Hepatic Lipotoxicity
Authors:
- 28 April 2025
- journal article
- research article
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- p. 1-24
Abstract
Breast cancer (BC) is the most common type of cancer in women. Researchers have studied various types of inhibitors of the MAPK/ERK signaling pathway, which plays an important role in the growth of BC cells. PD98059 is a potent and selective inhibitor of MEK, which may have potential application in the combined treatment of BC along with doxorubicin and Taxotere. The aim of this study was to provide a new insight into hepatotoxicity caused by doxorubicin, Taxotere, and PD98059 mono/combination therapy in a hepatoma in vitro model. HepG2 cells were treated with appropriate doses of used drugs. The expression of FASN and SCD1 lipogenic genes was measured by real-time PCR. The fatty acid composition PL and triglyceride fractions were analyzed using gas–liquid chromatography. The indicators of oxidative stress and antioxidant defense systems were measured by the calorimetric method. Doxorubicin and Taxotere significantly decreased FASN expression and increased SCD1 expression. Additionally, the combination of PD98059 alone, in combination with doxorubicin, or doxorubicin and Taxotere significantly increased the expression of SCD1. However, the combination of PD98059 and Taxotere significantly decreased this expression. PD98059 alone also dramatically increased the expression of FASN. In the PL fraction, doxorubicin, Taxotere, or PD98059 increased the percentage of saturated fatty acids and decreased the relative amount of unsaturated fatty acids alone. The doxorubicin + PD98059 combination also enhanced the effect of doxorubicin on PL SFAs and UFAs. Taxotere also reduced the SFAs and increased UFAs in the triglyceride fraction, which was also neutralized by PD98059 addition. Based on these findings, increased expression of SCD1 and elevated levels of SFAs in lipid fractions may indicate the possibility of hepatic lipotoxicity in BC patients, which necessitates the narrow monitoring of steatohepatitis in these patients.Keywords
Funding Information
- Tabriz University of Medical Sciences (67803)
This publication has 41 references indexed in Scilit:
- SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitorsBiomedicine & Pharmacotherapy, 2023
- Effect of differential deprivation of nutrients on cellular proliferation, oxidative stress, mitochondrial function, and cell migration in MDA-MB-231, HepG2, and HeLa cells3 Biotech, 2023
- The role of Stearoyl-CoA desaturase in hepatic de novo lipogenesisBiochemical and Biophysical Research Communications, 2022
- Fatty acids in multiple circulating lipid fractions reflects the composition of liver triglycerides in humansClinical Nutrition, 2022
- Selenium Diminishes Docetaxel-Induced Cell Death, Oxidative Stress, and Inflammation in the Laryngotracheal Epithelium of the MouseBiological Trace Element Research, 2019
- Lipid Metabolism2019
- Elevated lipolysis in adipose tissue by doxorubicin via PPARα activation associated with hepatic steatosis and insulin resistanceEuropean Journal of Pharmacology, 2019
- ERK1 and ERK2 activation modulates diet-induced obesity in miceBiochimie, 2017
- Effects of bleomycin and antioxidants on the fatty acid profile of testicular cancer cell membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2016
- Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinomaMolecular Biology Reports, 2016